Status:
COMPLETED
Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia
Lead Sponsor:
Gary E. Stein, Pharm.D.
Collaborating Sponsors:
Forest Laboratories
Conditions:
Pneumonia, Bacterial
Community-acquired
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
This study will further analyze the use of ceftaroline for CABP and compare its potential to eradicate bacterial pathogens to standard fluoroquinolone therapy. The enhanced spectrum of ceftaroline com...
Eligibility Criteria
Inclusion
- non-pregnant adults (≥ 18 years old) with suspected CABP admitted to the hospital for parenteral antibiotic therapy.
- All patients will have a creatinine clearance (CrCl) \>50 ml/min.
Exclusion
- pregnant or nursing patients,
- allergy to penicillin/cephalosporin antibiotics,
- allergy to fluoroquinolones,
- renal or hepatic failure, or have received an antimicrobial in past 96h.
- Patients who require antibiotics other than the study drugs will also be excluded.
Key Trial Info
Start Date :
February 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2015
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT01524302
Start Date
February 1 2012
End Date
April 1 2015
Last Update
April 12 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sparrow Hospital
Lansing, Michigan, United States